Analyst consensus rating
ImageneBio Analyst Rating: Buy
IMA is rated Buy by 2 analysts with a $13.00 target. As of 2026-08-20.
Direct answer
ImageneBio's consensus rating is Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.00.
Forecast evidence checked August 20, 2026.
Get free ImageneBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.61
- Average price target
- $13.00
- High price target
- $24.00
- Low price target
- $2.00
- Low target gap
- -64.3%
- Target upside
- +131.7%
- High target gap
- +327.8%
- Target range width
- 392.2%
- Consensus rating
- Buy
- Analysts
- 2
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ImageneBio?
ImageneBio has a verified Buy consensus. The same dataset has an average price target of $13.00.
How far are ImageneBio's low and high targets from the recorded price?
The low target implies -64.3%, while the high target implies +327.8%.
How many analysts are included in ImageneBio's consensus?
The verified consensus includes 2 analysts.
How is ImageneBio's target upside or downside calculated?
The average target of $13.00 is divided by the recorded price of $5.61, then one is subtracted to produce +131.7%. This does not guarantee a future return.
When was ImageneBio's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.